MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$49,970K
Free Cash flow
-$49,871K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Share-based compensation expense
    • Depreciation and amortization
    • Operating lease right-of-use ass...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Research and development incenti...
    • Operating lease liabilities
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-50,333
-60,825
-20,154
-59,100
Share-based compensation expense
6,404
6,930
11,653
8,771
Depreciation and amortization
1,067
1,129
1,336
1,756
Deferred income tax provision (benefit)
326
-241
843
-46
Research and development incentives receivable
6,516
6,040
-31,287
7,614
Prepaid expenses and other assets
-469
-191
-4,130
1,375
Operating lease right-of-use assets
-588
-1,111
-1,190
-1,172
Accounts payable
-59
-3,838
-2,881
-5,070
Accrued expenses and other current liabilities
-597
-2,353
2,000
1,121
Operating lease liabilities
-711
-1,283
-1,410
-1,390
Deferred revenue
-244
-706
-47,340
-9,398
Net cash used in operating activities
-49,606
-65,925
-19,346
-71,173
Purchases of property and equipment
265
713
574
674
Net cash used in investing activities
-265
-713
-574
-674
Proceeds from the exercise of share options and settlement of restricted share units
1
12
33
1
Payments of finance lease obligations
51
66
48
31
Net cash used in financing activities
-50
-54
-15
-30
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-49
-1,944
-222
-1,249
Net decrease in cash, cash equivalents and restricted cash
-49,970
-68,636
-20,157
-73,126
Cash, cash equivalents and restricted cash at beginning of period
560,079
628,715
648,872
880,067
Cash, cash equivalents and restricted cash at end of period
510,109
560,079
628,715
648,872
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net decrease incash, cash...-$49,970K (68.39%↑ Y/Y)Share-based compensationexpense$6,404K (-66.37%↓ Y/Y)Depreciation andamortization$1,067K (-67.96%↓ Y/Y)Operating leaseright-of-use assets-$588K (73.69%↑ Y/Y)Prepaid expenses andother assets-$469K (-105.47%↓ Y/Y)Deferred income taxprovision (benefit)$326K (119.79%↑ Y/Y)Proceeds from theexercise of share options...$1K (-66.67%↓ Y/Y)Net cash used inoperating activities-$49,606K (68.83%↑ Y/Y)Net cash used ininvesting activities-$265K (75.95%↑ Y/Y)Net cash used infinancing activities-$50K (41.86%↑ Y/Y)Effect of exchange ratechanges on cash, cash...-$49K (-102.15%↓ Y/Y)Canceled cashflow$8,854K Canceled cashflow$1K Net loss-$50,333K (63.97%↑ Y/Y)Purchases of property andequipment$265K (-75.95%↓ Y/Y)Payments of finance leaseobligations$51K (-42.70%↓ Y/Y)Research and developmentincentives receivable$6,516K (-68.64%↓ Y/Y)Operating leaseliabilities-$711K (73.23%↑ Y/Y)Accrued expenses andother current...-$597K (-161.42%↓ Y/Y)Deferred revenue-$244K (98.04%↑ Y/Y)Accounts payable-$59K (-105.46%↓ Y/Y)

BICYCLE THERAPEUTICS PLC (BCYC)

BICYCLE THERAPEUTICS PLC (BCYC)